In multiply relapsed disease, patients may experience CD19low (several hundred molecules per cell) or negative leukemia, yet the expression level in most cases still exceeds the expression of CD22, an alternative CAR-targeted antigen [83,84]. This evidence concerns the gene CD22 and leukemia.